Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Steqeyma as the seventh Stelara biosimilar with an expected launch date of February 2025.

This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...